Hu Z, Feng Z, Liu S, He H, Dong Y, Fan Z
BMC Med. 2024; 22(1):605.
PMID: 39736728
PMC: 11687046.
DOI: 10.1186/s12916-024-03830-0.
Radford M, Estcourt L, Sirotich E, Pitre T, Britto J, Watson M
Cochrane Database Syst Rev. 2024; 5:CD011305.
PMID: 38780066
PMC: 11112982.
DOI: 10.1002/14651858.CD011305.pub3.
Uzay A, Gundogdu Y, Kosan B, Yetis T, Karti S
Cancer Med. 2024; 13(10):e7292.
PMID: 38752476
PMC: 11097247.
DOI: 10.1002/cam4.7292.
Mikulski D, Koscielny K, Drozdz I, Mirocha G, Nowicki M, Misiewicz M
Int J Mol Sci. 2024; 25(8).
PMID: 38673940
PMC: 11050045.
DOI: 10.3390/ijms25084355.
Zhao X, Xu Z, Li Z, Zhou X, Hu Y, Wang H
Cancer Med. 2024; 13(1):e6897.
PMID: 38164654
PMC: 10807553.
DOI: 10.1002/cam4.6897.
Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial.
Kurita N, Nishikii H, Maruyama Y, Suehara Y, Hattori K, Sakamoto T
Ann Hematol. 2023; 102(10):2895-2902.
PMID: 37589942
DOI: 10.1007/s00277-023-05410-3.
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.
Mei M, Palmer J, Tsai N, Simpson J, OHearn J, Stein A
Clin Lymphoma Myeloma Leuk. 2023; 23(9):e268-e276.
PMID: 37301631
PMC: 10524945.
DOI: 10.1016/j.clml.2023.05.011.
[Effectiveness of autologous hematopoietic stem cell transplantation in the treatment of high-risk neuroblastoma in children: a single-center clinical study].
Wang L, Chen K, Zhang N, Yang J, Zhang T, Shao J
Zhongguo Dang Dai Er Ke Za Zhi. 2023; 25(5):476-482.
PMID: 37272173
PMC: 10247195.
DOI: 10.7499/j.issn.1008-8830.2301005.
Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients.
Ma X, Xu Z, Han T, Zhang Y, Han W, Fu H
Front Immunol. 2023; 14:1173320.
PMID: 37234156
PMC: 10206175.
DOI: 10.3389/fimmu.2023.1173320.
Comparison of efficacies of haploidentical transplantation and matched sibling donor transplantation in treating T-cell lymphoblastic lymphoma.
Wei R, Fang J, Shi W, Lu X, Wu Y, Jiang S
Cancer Med. 2023; 12(9):10499-10511.
PMID: 36992548
PMC: 10225212.
DOI: 10.1002/cam4.5786.
Antibody based conditioning for allogeneic hematopoietic stem cell transplantation.
Saha A, Blazar B
Front Immunol. 2022; 13:1031334.
PMID: 36341432
PMC: 9632731.
DOI: 10.3389/fimmu.2022.1031334.
Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review.
Wong J, Liu A, Han C, Dandapani S, Schultheiss T, Palmer J
Front Oncol. 2022; 12:1003908.
PMID: 36263219
PMC: 9574324.
DOI: 10.3389/fonc.2022.1003908.
Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study.
Konishi T, Ogawa H, Najima Y, Hashimoto S, Kito S, Atsuta Y
Ann Med. 2022; 54(1):2616-2625.
PMID: 36254468
PMC: 9624256.
DOI: 10.1080/07853890.2022.2125171.
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.
Zhang H, Fan Z, Huang F, Han L, Xu Y, Xu N
J Clin Oncol. 2022; 41(2):343-353.
PMID: 36084276
PMC: 9839269.
DOI: 10.1200/JCO.22.00767.
Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia.
Kong F, Liu S, Liu L, Pi Y, Pei Y, Xu D
Front Oncol. 2022; 12:936985.
PMID: 36052229
PMC: 9425557.
DOI: 10.3389/fonc.2022.936985.
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide.
Al Malki M, Palmer J, Tsai N, Mokhtari S, Hui S, Tsai W
Blood Adv. 2022; 6(14):4098-4106.
PMID: 35838754
PMC: 9327543.
DOI: 10.1182/bloodadvances.2022007264.
Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission.
Stein A, Al Malki M, Yang D, Palmer J, Tsai N, Aldoss I
Transplant Cell Ther. 2022; 28(7):368.e1-368.e7.
PMID: 35398328
PMC: 9253081.
DOI: 10.1016/j.jtct.2022.03.025.
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma:....
Kim K, Lee J, Lee M, Kim H, Do Y, Park Y
Cancer Res Treat. 2022; 55(1):304-313.
PMID: 35381164
PMC: 9873313.
DOI: 10.4143/crt.2022.004.
Decitabine-Intensified Modified Busulfan/Cyclophosphamide Conditioning Regimen Improves Survival in Acute Myeloid Leukemia Patients Undergoing Related Donor Hematopoietic Stem Cell Transplantation: A Propensity Score Matched Analysis.
Li Z, Shi W, Lu X, Lu H, Cao X, Tang L
Front Oncol. 2022; 12:844937.
PMID: 35371981
PMC: 8966032.
DOI: 10.3389/fonc.2022.844937.
Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia.
Chen J, Zhang Y, Chen X, Pang A, Zhao Y, Liu L
Cancer Cell Int. 2022; 22(1):89.
PMID: 35189891
PMC: 8862236.
DOI: 10.1186/s12935-021-02410-z.